GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of gemcitabine,
pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or
advanced NK/T-cell lymphoma patients (ENKTCL).